Cannabis Law Report

AUGUST 17, 2021

–(BUSINESS WIRE)– $MRNS #MarinusPharma — Marinus Pharmaceuticals, Inc. We believe the totality of the data is encouraging and supports advancing to Phase 3. Data Highlights. The condition is caused by inherited mutations in either the TSC1 gene or the TSC2 gene. About Marinus Pharmaceuticals.

Pharmaceutical 98

Pharmaceutical Clinical Trials Treatment Patients 98

Cannabis Law Report

JANUARY 6, 2022

AUSTIN, Texas–(BUSINESS WIRE)– Anebulo Pharmaceuticals, Inc. He serves as the primary spokesperson and point of contact with the analyst and investment community and is also responsible for the timely dissemination of information and data to these important stakeholders. About Anebulo Pharmaceuticals, Inc.

Pharmaceutical 52

Pharmaceutical Clinical Trials Cannabinoids Programs 52

Puff Puff Post

MARCH 10, 2020

SOURCE InMed Pharmaceuticals Inc. About InMed: InMed Pharmaceuticals is a clinical stage pharmaceutical company developing a pipeline of cannabinoid-based medications, initially focused on the therapeutic benefits of cannabinol (CBN) in diseases with high unmet medical need.

Clinical Trials 84

Clinical Trials Pharmaceutical Research and Development Cannabinoids 84

Cannabis Law Report

NOVEMBER 12, 2021

AUSTIN, Texas–(BUSINESS WIRE)– Anebulo Pharmaceuticals, Inc. In compliance with current Good Manufacturing Practice requirements, the Company delivered ANEB-001’s active pharmaceutical ingredient to its contract manufacturer to fill into 10 mg and 50 mg capsules for finished product. About Anebulo Pharmaceuticals, Inc.

Pharmaceutical 52

Pharmaceutical Clinical Trials Business Research and Development 52

Cannabis Law Report

JANUARY 3, 2022

AUSTIN, Texas–(BUSINESS WIRE)– Anebulo Pharmaceuticals, Inc. We were able to rapidly incorporate the FDA’s feedback into the design of the current Phase 2 trial to make the data generated in Europe as relevant as possible for a potential future NDA submission. About Anebulo Pharmaceuticals, Inc. Rex Merchant.

Pharmaceutical 52

Pharmaceutical Cannabinoids Treatment Clinical Trials 52

Cannabis Law Report

SEPTEMBER 24, 2019

Here is the BBC report and below you will find the full press release from GW Pharmaceuticals. Epidyolex has been approved as a treatment option for children as young as two with Lennox-Gastaut syndrome or Dravet syndrome – difficult-to-treat conditions that can cause multiple seizures a day. ” Source BBC: [link].

Pharmaceutical 55

Pharmaceutical Epilepsy Research and Development Medicine 55

The Cannigma

NOVEMBER 23, 2021

The app helps patients make sense of their journey by simplifying the information and supplying data-driven insights into their regimen and its effects. We delve into how data can further our understanding of different types of cannabis and why standardization is desperately needed in the industry.

Data 52

Data Patients Access Wellness and Beauty 52

Cannabis Law Report

JULY 19, 2021

The data from the study is expected to be embedded into the RYAH MD platform, with the goal of enabling healthcare professionals to administer THC, CBD and terpenes in milliliters, which are then expected to automatically be converted into milligrams to allow for a customized, targeted patient inhalation session. billion by 2027.

Therapy 76

Therapy Data Research and Development Events 76

Cannabis Law Report

SEPTEMBER 13, 2021

BALTIMORE–(BUSINESS WIRE)– MyMD Pharmaceuticals, Inc. Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan, today announced that it intends to initiate dosing for a Phase 2 trial of MYMD-1’s function in delaying aging early in the fourth quarter of 2021.

Clinical Trials 52

Clinical Trials Pharmaceutical Research and Development Therapy 52

Cannabis Law Report

NOVEMBER 16, 2021

Phase 2 trial recruiting begins immediately; efficacy data expected by the end of the first quarter of 2022. BALTIMORE–(BUSINESS WIRE)– MyMD Pharmaceuticals, Inc. Recruitment for the Phase 2 trial will begin immediately, and efficacy data is expected by the end of first quarter of 2022. “To MyMD Pharmaceuticals, Inc.

Pharmaceutical 52

Pharmaceutical Clinical Trials Research and Development Therapy 52

Cannabis Law Report

JUNE 23, 2021

RYAH is pleased to contribute RYAH’s IoT devices and data platform and work with Medicann toward perfecting prescribing practices and dosing regimens,” said Gregory Wagner , CEO of RYAH Group, Inc. With a strong IP portfolio, RYAH gathers deep and insightful data on the complete patient session and formulation life cycle.

Programs 100

Programs Data Events Collective 100

Cannabis Law Report

JUNE 1, 2021

Given the size and scale of the study, RYAH has developed a custom software solution, using OAuth API-integration to protect the privacy of the participants in the study, with the goal of enabling a fully integrated, patient feedback and data collection capability. About RYAH Group, Inc. RYAH Group, Inc.

Clinical Trials 89

Clinical Trials Chronic Pain Data Research and Development 89

Cannabis Law Report

OCTOBER 26, 2021

BALTIMORE–(BUSINESS WIRE)– MyMD Pharmaceuticals, Inc. Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan, announced today that Chris Chapman, M.D., Chapman has operated Chapman Pharmaceutical Consulting, Inc., About MyMD Pharmaceuticals, Inc.

Pharmaceutical 52

Pharmaceutical Clinical Trials Research and Development Therapy 52

Cannabis Law Report

JANUARY 4, 2022

Assay”) as a Laboratory Developed Test (LDT), pending a final review of the assay’s validation data by NYSDOH. With the conditional approval, ADCL can immediately employ the Linea 2.0 With the conditional approval, ADCL can immediately employ the Linea 2.0 Assay (the “Linea 2.0 The Linea 2.0 The performance of the Linea 2.0

Conditions 52

Conditions Research and Development Therapy Supply Chain 52

Puff Puff Post

MARCH 10, 2020

SOURCE InMed Pharmaceuticals Inc. About InMed: InMed Pharmaceuticals is a clinical stage pharmaceutical company developing a pipeline of cannabinoid-based medications, initially focused on the therapeutic benefits of cannabinol (CBN) in diseases with high unmet medical need.

Clinical Trials 40

Clinical Trials Pharmaceutical Research and Development Cannabinoids 40

Veriheal

JULY 12, 2021

According to the American Psychiatric Association , PTSD is a “psychiatric disorder that may occur in people who have experienced or witnessed a traumatic event such as natural disaster, as a serious accident, a terrorist act, war/combat or rape or who have been threatened with death, sexual violence or serious injury”.

Treatment 104

Treatment Sleep Clinical Trials Data 104

Project CBD

FEBRUARY 28, 2023

HerbalGram, the acclaimed quarterly journal of the American Botanical Council, recently published its 2021 “Herb Market Report,” which included data on sales of CBD as an herbal ingredient in mainstream and natural retail channels in the United States. Consumers spent roughly $31.3 increase in annual sales. Accessed July 25, 2021.

CBD 144

CBD Seed-To-Sale Food Access 144

The Joint Blog

DECEMBER 20, 2020

“Respondents reported a median score of 90 on a zero to 100-point scale in response to the question, “How does cannabis affect your conditions or symptoms overall?” Materials and Methods: A cross-sectional online survey of those using cannabis for health-related conditions run between May and July 2019.

Sleep 49

Sleep Data Pharmaceutical Marijuana 49

Cannabis Law Report

JUNE 16, 2021

This engagement will build on the strong foundation on Santé, having treated more than 10,000 patients since 2014 under a real-world data protocol. Training will be provided within the research program for licensed practitioners to assess the safety of psychedelic medicines and to classify and report positive and adverse events.

Clinical Trials 104

Clinical Trials Therapy Research and Development Events 104

Cannabis Law Report

OCTOBER 6, 2021

Flora Pharma will seek to identify scientific gaps in the cannabis industry and ultimately work to translate that to pharmaceutical cannabis products backed by data. The immediate next steps are to submit data for ethics committee review and approval whereupon acceptance, further details will be provided. “A

Clinical Trials 52

Clinical Trials Research and Development Pharmaceutical Events 52

Cannabis Law Report

JULY 19, 2021

1 All sales figured sourced from BDSA Sales Data and the Company’s internal calculations. 2 All sales figures sourced from the May 2021 BDSA Sales Data. With a potential maximum licensed canopy area of 200 hectares (495 acres), Bophelo has scalability that is arguably unmatched in the world today.

Collective 105

Collective Data Cultivation Events 105

Cannabis Law Report

AUGUST 14, 2021

This partnership marks Mary AG’s first application of farm-level technology, taking its knowledge in automated systems and applying that expertise to a holistic, controlled growing condition that incorporates automated plant health assessment. Working with CBDer on potential non-China greenhouse projects. CSE: MARY).

Hemp 105

Hemp Supply Chain Cannabinoids Extraction 105

SpeedWeed

MARCH 13, 2021

Parkinson’s disease patients typically use pharmaceutical medications to treat their condition with varying degrees of success. To learn more about the effectiveness of cannabis as a treatment for PD, a survey was sent to more than 7,600 people who had interacted with the Parkinson’s Foundation through events or the group’s helpline.

Patients 52

Patients Treatment Therapy Sleep 52

Project CBD

MAY 3, 2023

CannMed: For what conditions do you think CBG has the most promise? It’s noteworthy that much of this anecdotal data is supported by findings from preclinical research. Psoriasis is a well-known condition where people get not only joint pain but they also get these thick red patches and scales on their skin.

Cannabinoids 209

Cannabinoids Sleep Clinical Trials CBD 209

Cannabis Law Report

JULY 28, 2021

The study was conducted by a respected contract research organization with deep expertise in preclinical oncology model development and drug testing and data corresponding to all studied cancer cell lines have now been reported to the Company. ” Next Steps. About PharmaDrug Inc.

Research and Development 105

Research and Development Clinical Trials Treatment Pharmaceutical 105

Puff Puff Post

NOVEMBER 5, 2019

5, 2019 /CNW/ – InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (TSX: IN; OTCQX: IMLFF), today announced the filing of a Clinical Trial Application (“CTA”) in the Netherlands to initiate a Phase 1 human clinical trial for INM-755 in healthy volunteers. VANCOUVER, Nov.

Clinical Trials 40

Clinical Trials Pharmaceutical Cannabinoids Data 40

Cannabis Law Report

FEBRUARY 2, 2022

Cannabis represents a potential cornucopia of medicinal and pharmaceutical advancement. The ability to take cannabis compounds distilled into their pure forms, and then recombine them into specific, purposeful end-products could have significant potential for the pharmaceutical industry in the future. “We BILLERICA, Mass.,

Extraction 52

Extraction Pharmaceutical Hemp Cultivation 52

Cannabis Law Report

AUGUST 23, 2021

FDA has not reviewed the manufacturing process of these unapproved CBD-containing drug products, so the manufacturing conditions of, or contaminant levels in, these products is unknown. He added that significant data is still needed to inform policy regarding use of consumer cannabis products.

Pets 105

Pets Hemp CBD Food 105

The Cannigma

OCTOBER 9, 2021

Prolonged bladder emptying due to cannabinoid supplementation might translate into a probable solution for various urinary conditions, or may worsen conditions in which the bladder is already struggling to release urine. The reasoning for such infliction is multifactorial but more common in women over the age of 50.

Cannabinoids 86

Cannabinoids Consumption Patients Cannabis 86

Cannabis Law Report

FEBRUARY 9, 2022

These are the very first draft rules that we’re seeing, so it really is a kind of pivotal event.”. But this is the first time Oregonians have been allowed to see some of the nuts and bolts of what some predict could grow into a billion-dollar industry nationally, according to Data Bridge Market Research.

Clinical Trials 52

Clinical Trials Microdosing Safety Conditions 52

Cannabis Law Report

NOVEMBER 12, 2021

THE Chairman of a recently-listed UK pharmaceutically-focused cannabis company has stood down after a breach of market rules. In the event that the Maximum LTV is exceeded, Brown Shipley can make a call on the Guarantors requiring them to place cash with Brown Shipley for the aggregate amount of the excess exposure over the Maximum LTV.

Cannabinoids 98

Cannabinoids Clinical Trials Research and Development Pharmaceutical 98

Cannabis Law Report

JUNE 7, 2021

1.526 were reduced as expected and consistent with other CDC-reported data on vaccine-induced antibody neutralization against these variants 1. Key end-markets include textiles, pharmaceuticals and nutraceuticals, and cannabis, among others. The study showed neutralizing antibody titers against B.1.1.7 Dr. James A.

Clinical Trials 64

Clinical Trials Research and Development Therapy Supply Chain 64

Cannabis Law Report

OCTOBER 12, 2021

Their audacious vision to reimagine traditional pharma efficacy trials promises to rapidly and accurately determine which nutraceuticals and natural molecules actually work for which conditions,” said Diamandis. What we’ve accomplished thus far is only the beginning!”. Media Contact: Eric Schudiske ( eric@s2spr.com ).

Clinical Trials 52

Clinical Trials Research and Development Sleep Cannabinoids 52

Puff Puff Post

SEPTEMBER 16, 2019

Event details below: Date: Tuesday, September 17th 2019. As a Contract Research Organization specialized in medical cannabis, Santé Cannabis offers consultation, data management and clinical trial services to a diverse range of clients from pharmaceutical, biotech and cannabis industries. Time: 9:00AM to 5:00PM.

Programs 108

Programs Research and Development Education Treatment 108

Cannabis Law Report

MARCH 29, 2020

At an HIV Community Cannabis Education event held in Toronto, a cannabis company proudly declared their company had not had a single product recall to date. triggering new innovations and improved data quality through better user experiences. triggering new innovations and improved data quality through better user experiences.

Compliance 69

Compliance Compliance Supply Chain Research and Development 69

Cannabis Law Report

FEBRUARY 2, 2022

post-pandemic owing to increasing demand from the pharmaceutical sector and rising awareness among consumers regarding health.” ( See [link] ). Investor information is available at www.olb.com/investors-data and www.Dmint.com. Hemp-derived CBD is expected to grow at a CAGR of 23.4% Safe Harbor Statement.

eCommerce 52

eCommerce CBD Environment Pharmaceutical 52

Cannabis Law Report

JANUARY 21, 2022

The Assay previously received conditional approval from the New York State Department of Health in late December 2021. Key end-markets include textiles, pharmaceuticals and nutraceuticals, and cannabis, among others. The Linea 2.0 Assay is a high-throughput multiplex RT-PCR assay targeting the E and N genes of SARS-CoV-2.

Collective 52

Collective Therapy Research and Development Supply Chain 52